Department of Nephrology, The First Affiliated Hospital of Chongqing Medical University, Youyi Road 1, Chongqing 400042, China.
Clinics (Sao Paulo). 2021 Mar 24;76:e1876. doi: 10.6061/clinics/2021/e1876. eCollection 2021.
Although previous studies have indicated that statin therapy can effectively prevent the development of CIN, this observation remains controversial, especially in high-risk patients. A meta-analysis was performed to evaluate the efficacy of statin pretreatment for preventing the development of CIN in patients with chronic kidney disease (CKD) and to determine its effectiveness in various subgroups. We searched the online databases PubMed, EMBASE, and the Cochrane Library. RCTs that involved the comparison of the short-term moderate or high-dose statin pretreatment with placebo for CIN prevention in CKD patients undergoing angiography were included. The primary outcome was CIN prevalence. Seven RCTs comprising 4256 participants were investigated in this analysis. The risk of developing CIN in patients pretreated with statins was significantly lower than that in patients pretreated with placebo (RR=0.57, 95%CI=0.43-0.76, p=0.000). The SCr values of the statin group, when analyzed 48h after angiography were lower than those of the placebo group ((SMD=-0.15, 95% CI=-0.27 to -0.04, p=0.011). In the subgroup analysis, statin pretreatment could decrease the risk of CIN in CKD patients with DM (RR=0.54, 95% CI=0.39-0.76, p=0.000), but not in CKD patients without DM (RR=0.84, 95% CI=0.44-1.60, p=0.606). The efficacy of atorvastatin for preventing CIN was consistent with that observed with the use of rosuvastatin. The risk ratios (RR) were 0.51 (95% CI=0.32-0.81, p=0.004) and 0.60 (95% CI=0.41-0.88, p=0.009), respectively. Our study demonstrated that statin pretreatment could prevent the development of CIN in CKD patients. However, subgroup analysis demonstrated that statin pretreatment, despite being effective in preventing CIN in patients with CKD and DM, was not helpful for CKD patients without DM. Rosuvastatin and atorvastatin exhibited similar preventive effects with respect to CIN.
尽管先前的研究表明他汀类药物治疗可有效预防 CIN 的发生,但这一观察结果仍存在争议,尤其是在高危患者中。本研究进行了一项荟萃分析,旨在评估他汀类药物预处理预防慢性肾脏病(CKD)患者 CIN 发展的疗效,并确定其在各亚组中的有效性。我们检索了在线数据库 PubMed、EMBASE 和 Cochrane Library。纳入了比较短期中或高剂量他汀类药物预处理与安慰剂预防 CKD 患者血管造影后 CIN 的 RCT。主要结局是 CIN 发生率。本分析共纳入了 7 项 RCT,共 4256 名参与者。与安慰剂预处理相比,他汀预处理患者发生 CIN 的风险显著降低(RR=0.57,95%CI=0.43-0.76,p=0.000)。血管造影后 48 小时,他汀组的 Scr 值低于安慰剂组(SMD=-0.15,95%CI=-0.27 至-0.04,p=0.011)。在亚组分析中,他汀预处理可降低 CKD 合并糖尿病(DM)患者发生 CIN 的风险(RR=0.54,95%CI=0.39-0.76,p=0.000),但对 CKD 合并 DM 患者无此作用(RR=0.84,95%CI=0.44-1.60,p=0.606)。阿托伐他汀预防 CIN 的疗效与瑞舒伐他汀一致。风险比(RR)分别为 0.51(95%CI=0.32-0.81,p=0.004)和 0.60(95%CI=0.41-0.88,p=0.009)。本研究表明,他汀预处理可预防 CKD 患者 CIN 的发生。然而,亚组分析表明,他汀预处理虽然对 CKD 合并 DM 患者预防 CIN 有效,但对 CKD 合并 DM 患者无效。瑞舒伐他汀和阿托伐他汀在预防 CIN 方面具有相似的效果。